Alpha Teknova, Inc. (NASDAQ:TKNO) Shares Acquired by Northern Trust Corp

Northern Trust Corp grew its stake in Alpha Teknova, Inc. (NASDAQ:TKNO) by 31.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,196 shares of the company’s stock after purchasing an additional 9,383 shares during the quarter. Northern Trust Corp owned approximately 0.07% of Alpha Teknova worth $327,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Invesco Ltd. acquired a new stake in shares of Alpha Teknova in the fourth quarter valued at about $9,236,000. Susquehanna International Group LLP grew its position in shares of Alpha Teknova by 472.5% in the fourth quarter. Susquehanna International Group LLP now owns 209,409 shares of the company’s stock valued at $1,749,000 after purchasing an additional 172,828 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Alpha Teknova in the fourth quarter valued at about $716,000. Nkcfo LLC acquired a new stake in shares of Alpha Teknova in the fourth quarter valued at about $501,000. Finally, Tradewinds LLC. acquired a new stake in shares of Alpha Teknova in the fourth quarter valued at about $383,000. Institutional investors and hedge funds own 13.81% of the company’s stock.

Alpha Teknova Stock Performance

TKNO opened at $5.76 on Monday. The firm has a market capitalization of $307.82 million, a PE ratio of -7.78 and a beta of 0.50. Alpha Teknova, Inc. has a twelve month low of $1.16 and a twelve month high of $10.37. The firm’s 50-day moving average price is $5.94 and its 200 day moving average price is $7.05. The company has a current ratio of 4.73, a quick ratio of 3.94 and a debt-to-equity ratio of 0.12.

Alpha Teknova (NASDAQ:TKNO) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. The firm had revenue of $9.60 million for the quarter, compared to analyst estimates of $9.41 million. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. As a group, sell-side analysts expect that Alpha Teknova, Inc. will post -0.58 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Craig Hallum started coverage on shares of Alpha Teknova in a research report on Monday, February 10th. They issued a “buy” rating and a $12.00 target price on the stock.

Alpha Teknova Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.